IP Group has poured more funding into Istesso, whose treatment for rheumatoid arthritis traces its roots to an Aberdeen spinout, to drive immuno-metabolism therapies for autoimmune diseases.

Johnson & Johnson and BioMotiv have provided $13m of funding to help Aro develop protein-based therapeutics aimed at treating cancer.

Spun out of UC Berkeley research, Magnetic Insight is commercialising an in vivo molecular imaging technology that operates by applying magnetic fields to iron oxide tracers.

Uniseed has returned to back Csiro digital health spinout Cardihab after an earlier round which also raised $1.4m in 2017.

10X Genomics has purchased genomic analysis platform Spatial Transcriptomics, based on research at Karolinska Institute and KTH Royal Institute of Technology.

ICL-founded Accunea hopes to commercialise a medical device enabling clinicians to catch acute kidney injuries earlier than currently possible.

Asgard Therapeutics will develop cancer therapies which use reprogrammed human skin cells to improve the immune system’s capacity to identify cancerous particles.

Drug discovery technology provider Genomics has closed a second tranche of its oversubscribed series B round to increase its size to $41.7m.

AstraZeneca, Merck & Co and Alexion all scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.

The gut-brain therapy developer has closed a $21m extension to its series B round backed by Illumina and Alexandria Real Estate Equities.